NASDAQ:XOMAXOMA Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding XOMA Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.25 +0.04 (+0.19 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$20.49Now: $21.25▼$21.5450-Day Range$18.51MA: $22.23▼$25.5152-Week Range$14.03Now: $21.25▼$28.85Volume26,239 shsAverage Volume53,271 shsMarket Capitalization$234.07 millionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.50, XOMA has a potential upside of 38.8% from its current price of $21.25.Amount of Analyst CoverageXOMA has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesXOMA has received 408 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXOMA has received 403 “underperform” votes. (Add your “underperform” vote.)Community SentimentXOMA has received 50.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote “Outperform” if you believe XOMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,008,822.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.89% of the stock of XOMA is held by insiders.Percentage Held by Institutions43.71% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.60) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -17.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -17.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:XOMA Previous Symbol CUSIP98419J10 CIK791908 Webwww.xoma.com Phone510-204-7200Debt Debt-to-Equity Ratio0.62 Current Ratio5.57 Quick Ratio5.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.37 million Price / Sales12.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book4.22Profitability EPS (Most Recent Fiscal Year)($0.23) Net Income$-1,980,000.00 Net Margins-102.32% Return on Equity-34.27% Return on Assets-12.84%Miscellaneous Employees11 Outstanding Shares11,015,000Market Cap$234.07 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:XOMA Rates by TradingView Receive XOMA News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. XOMA (NASDAQ:XOMA) Frequently Asked Questions How has XOMA's stock been impacted by COVID-19 (Coronavirus)? XOMA's stock was trading at $19.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XOMA shares have increased by 9.0% and is now trading at $21.25. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of XOMA? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA. When is XOMA's next earnings date? XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA. How were XOMA's earnings last quarter? XOMA Corp (NASDAQ:XOMA) posted its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.33. The biotechnology company earned $0.80 million during the quarter, compared to analysts' expectations of $3.40 million. XOMA had a negative net margin of 102.32% and a negative return on equity of 34.27%. View XOMA's earnings history. What price target have analysts set for XOMA? 2 brokers have issued 12-month price objectives for XOMA's shares. Their forecasts range from $29.00 to $30.00. On average, they expect XOMA's share price to reach $29.50 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View analysts' price targets for XOMA. Has XOMA been receiving favorable news coverage? Press coverage about XOMA stock has trended somewhat positive on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. XOMA earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutXOMA. Who are some of XOMA's key competitors? Some companies that are related to XOMA include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), TransEnterix (TRXC), Opko Health (OPK), Gilead Sciences (GILD), Uranium Energy (UEC), Ekso Bionics (EKSO) and NXP Semiconductors (NXPI). Who are XOMA's key executives? XOMA's management team includes the following people: Mr. James R. Neal, CEO & Director (Age 63)Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)Dr. Deepshikha Datta, Chief Bus. Officer What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." Who are XOMA's major shareholders? XOMA's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (1.89%), BlackRock Inc. (1.78%), Geode Capital Management LLC (0.54%), Cadence Capital Management LLC (0.50%), EAM Investors LLC (0.36%) and Invesco Ltd. (0.29%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View institutional ownership trends for XOMA. Which major investors are selling XOMA stock? XOMA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Two Sigma Investments LP, Geode Capital Management LLC, BlackRock Inc., Alps Advisors Inc., First Manhattan Co., and EAM Investors LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns. View insider buying and selling activity for XOMA. Which major investors are buying XOMA stock? XOMA stock was acquired by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Invesco Ltd., Stonepine Capital Management LLC, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, and Value Fund L P Biotechnology. View insider buying and selling activity for XOMA. How do I buy shares of XOMA? Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $21.25. How big of a company is XOMA? XOMA has a market capitalization of $234.07 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe. What is XOMA's official website? The official website for XOMA is www.xoma.com. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
